Printed from

Costly gene therapies raise questions about affordability, coverage

Posted On: Sep. 27, 2022 10:16 AM CST

As new multimillion-dollar gene therapies continue hitting the market, it's unclear how small employers, state Medicaid programs, and the rest of the health system will absorb such large costs all at once, Axios reports. The Food and Drug Administration recently approved two multimillion-dollar gene therapies from Bluebird Bio Inc. – one costing $2.8 million and the other $3 million.